250274-91-0

Basic information

• Product Name: Azetidine-2-Methanol
• Synonyms: Azetidine-2-Methanol;Azetidin-2-ylmethanol HCl
• CAS NO: 250274-91-0
• Molecular Formula: C4H9NO
• Molecular Weight: 87.12036
• Mol File: 250274-91-0.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 151.9±13.0 °C(Predicted)
• Appearance: /
• Density: 1.017±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 14.77±0.10(Predicted)
• CAS DataBase Reference: Azetidine-2-Methanol(CAS DataBase Reference)
• NIST Chemistry Reference: Azetidine-2-Methanol(250274-91-0)
• EPA Substance Registry System: Azetidine-2-Methanol(250274-91-0)

Safety Data

• Hazardous Substances Data: 250274-91-0(Hazardous Substances Data)

Usage

General Description

Azetidine-2-methanol, also known as 3-hydroxy-1-azetidine methanol, is a chemical compound with potential pharmaceutical and industrial applications. This heterocyclic compound contains a four-membered ring with a nitrogen atom and a hydroxyl group attached to one of the carbon atoms. It is a colorless liquid at room temperature and is soluble in water. Azetidine-2-methanol has been studied for its potential as a chiral building block in organic synthesis and as a precursor for the synthesis of various pharmaceuticals and other fine chemicals. Its unique structure and properties make it a valuable intermediate in chemical and pharmaceutical production.

Upstream product

• 503-29-7 azetidine 
• 50-00-0 formaldehyd 
• 766483-76-5 azetidine-2-carboxylic acid ethyl ester 
• 2133-34-8 (2S)-azetidine-2-carboxylic acid 
• 95729-87-6 benzyl (2R)-4-oxoazetidine-2-carboxylate 
• 69684-69-1 (S)-Azetidin-2-carbonsaeuremethylester-hydrochlorid 
• 162698-26-2 azetidine-2-carboxylic acid methyl ester hydrochloride 

Downstream Products

• 161511-90-6 (R)-1-t-butyloxycarbonyl-2-azetidinemethanol 
• 161511-85-9 2-(S)-hydroxymethyl-azetidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS

The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing said compounds.

Development of 99mTc radiolabeled A85380 derivatives targeting cerebral nicotinic acetylcholine receptor: Novel radiopharmaceutical ligand 99mTc-A-YN-IDA-C4

Nicotinic acetylcholine receptors (nAChRs) are pentameric ligand-gated ion channels that have been implicated in higher brain functions. To elucidate the functional mechanisms underlying nAChRs and contribute significantly to development of drugs targeting neurological and neuropsychiatric diseases, non-invasive nuclear medical imaging can be used for evaluation. In addition, technetium-99m (99mTc) is a versatile radionuclide used clinically as a tracer in single-photon emission computed tomography. Because A85380 is known as a potent α4β2-nAChR agonist, we prepared A85380 derivatives labeled with 99mTc using a bifunctional chelate system. A computational scientific approach was used to design the probe efficiently. We used non-radioactive rhenium (Re) for a 99mTc analog and found that one of the derivatives, Re-A-YN-IDA-C4, exhibited high binding affinity at α4β2-nAChR in both the docking simulation (?19.3 kcal/mol) and binding assay (Ki = 0.4 ± 0.04 nM). Further, 99mTc-A-YN-IDA-C4 was synthesized using microwaves, and its properties were examined. Consequently, we found that 99mTc-A-YN-IDA-C4, with a structure optimized by using computational chemistry techniques, maintained affinity and selectivity for nAChR in vitro and possessed efficient characteristics as a nuclear medicine molecular imaging probe, demonstrated usefulness of computational scientific approach for molecular improvement strategy.

AURORA KINASE COMPOUNDS AND METHODS OF THEIR USE

Provided herein are pyrrolotriazine compounds for treatment of Aurora kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.